Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astria Therapeutics (ATXS) Liabilities and Shareholders Equity: 2017-2019

Historic Liabilities and Shareholders Equity for Astria Therapeutics (ATXS) over the last 3 years, with Sep 2019 value amounting to $43.8 million.

  • Astria Therapeutics' Liabilities and Shareholders Equity fell 1.94% to $43.8 million in Q3 2019 from the same period last year, while for Sep 2019 it was $186.0 million, marking a year-over-year increase of 41.22%. This contributed to the annual value of $39.2 million for FY2018, which is 118.86% up from last year.
  • As of Q3 2019, Astria Therapeutics' Liabilities and Shareholders Equity stood at $43.8 million, which was down 9.67% from $48.5 million recorded in Q2 2019.
  • Astria Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $54.5 million for Q1 2019, and its period low was $17.9 million during Q4 2017.
  • In the last 3 years, Astria Therapeutics' Liabilities and Shareholders Equity had a median value of $39.2 million in 2018 and averaged $36.8 million.
  • As far as peak fluctuations go, Astria Therapeutics' Liabilities and Shareholders Equity slumped by 45.28% in 2018, and later spiked by 197.96% in 2019.
  • Astria Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $17.9 million in 2017, then surged by 118.86% to $39.2 million in 2018, then dropped by 1.94% to $43.8 million in 2019.
  • Its last three reported values are $43.8 million in Q3 2019, $48.5 million for Q2 2019, and $54.5 million during Q1 2019.